HomeNews

News

FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment...

The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab...

Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered Antibodies

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020,...

Annual World ADC – Best New Drug Developer 2020: Sutro Biopharma’s Journey to Success

From liquid biopsies to precision medicine to immunology, the field of cancer treatment has experienced significant progress during the...

Merck Acquires VelosBio and Strengthens Oncology Pipeline with Investigational Antibody-Drug Conjugates

Merck & Co (MSD) has agreed to acquire VelosBio, a privately held clinical-stage biopharmaceutical company, for U.S. $ 2.75...

CStone Pharmaceuticals and LegoChem Biosciences Enter Global Licensing Agreement for LCB71

Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive...

FDA Grants Priority Review for Trastuzumab deruxtecan in HER2 Positive Metastatic Gastric Cancer

The U.S. Food and Drug Administration (FDA) has granted Priority Review for Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; DS-1062; Enhertu®; Daiichi...

Gilead Finalizes Acquisition of Immunomedics

Earlier today Foster City, California-based Gilead Sciences confirmed that it had completed the previously announced transaction to acquire Immunomedics...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize Mirvetuximab Soravtansine

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in...

IMGN632 Receives Breakthrough Therapy Designation in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632, a novel CD123-targeting Antibody-drug Conjugate...
Seattle Genetics

Seattle Genetics Changes Corporate Name to Seagen

Seattle Genetics confirmed that it has changed it's corporate name to Seagen. According to a statement issued by the...